HOME >> BIOLOGY >> NEWS
Nitric Oxide May Hold Key To First Treatment For Deadly Form Of Malaria, Duke Scientists Report

" Hausladen said.

The actions of NO in this experiment also resemble the process by which oxygen affects cell health and disease, the scientists say.

"Now we have demonstrated that an NO group, attached to a thiol within a cell, has regulatory function," Stamler said. "There has been growing evidence that NO does its work in the body by signaling genes, but no one has found proof before this."

Both oxygen and NO are vital to life processes, but too much of either can damage cells. To keep the amount of oxygen and NO in balance, cells have built-in systems to eliminate the excess. One way to do that is to have transcription factor sensors that get turned on when too much oxygen or NO is present.

In fact, bacterial cells attempt to control both excess oxygen and excess nitrogen with the same OxyR transcription factor.

In human cells, constant vigilance against excess oxygen and NO takes a toll over time. When the system is out of balance, perhaps when a transcription factor is mutated, disease can result, the scientists say.

"It is a parallel process to what is known as oxidative stress, in which an excess of oxygen in cells can lead to a host of diseases, as well as the cumulative damage we call aging," Stamler said. "NO has a similar deleterious function, which we call nitrosative stress. When a cell can't contain the flow of SNO, the nitrosative stress can well be theorized to contribute to cancer, arthritis, neurodegenerative diseases, stroke and hardening of the arteries -- all diseases associated with NO."


'"/>

Contact: Karyn Hede George
georg016@mc.duke.edu
919-660-1301
Duke University Medical Center
14-Aug-1996


Page: 1 2 3 4

Related biology news :

1. Nitric oxide may change basic understanding of cellular machinery
2. Nitric oxide has important role in fever regulation, new study says
3. Nitric oxide-like drug could revive a failing heart
4. The building blocks of erection: Nitric oxide...and more nitric oxide
5. Nitric Oxide Found To Control Cells By Turning On Genes; Suggests New Role In Health And Disease
6. Duke Researchers Discover Central Role Of Nitric Oxide In Hemoglobin Action
7. First glimpse of DNA binding to viral enzyme
8. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
9. 2nd media alert First Scientific Conference on Childhood Leukaemia
10. First International Scientific Conference on Childhood Leukaemia
11. First ever standards linking climate change, biodiversity and poverty seek global peer review

Post Your Comments:
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 ... (PCR) represents one of the fastest growing technologies in ... biologists in subcellular visualization is driving growth in nucleic ... for deeper understanding of gene expressions will continue to ... Expanding applications in fields ranging from pharma, biotech, food ...
(Date:3/4/2015)... 4, 2015 Lancée ... Paris en décembre 2011, l,étude collaborative ... », qui compare   l es microsphères ... sorafénib dans le carcinome hépatocellulaire avancé, a recruté ... foie avancé   ; les résultats sont attendus ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
Cached News: